Cresco Labs (FRA:6CQ) 3-Year RORE % : -11.20% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6CQ Cresco Labs Inc FRA:6CQ
42 GF Score
Price €0.60
GF Value €0.78
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cresco Labs 3-Year RORE %?

Cresco Labs FRA:6CQ -1.16% 42 3-Year RORE % is -11.20 as of Mar. 2026. GuruFocus rates FRA:6CQ with a GF Score™ of 42/100 and a GF Value™ of €0.78 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 937 Drug Manufacturers companies, Cresco Labs ranks worse than 58.27% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Cresco Labs's 3-Year RORE % for the quarter that ended in Mar. 2026 was -11.20%.

The industry rank for Cresco Labs's 3-Year RORE % or its related term are showing as below:

FRA:6CQ's 3-Year RORE % is ranked worse than
58.27% of 937 companies
in the Drug Manufacturers industry
Industry Median: 3.17 vs FRA:6CQ: -11.20

Cresco Labs  (FRA:6CQ) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Cresco Labs 3-Year RORE % Related Terms


Cresco Labs 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Cresco Labs's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cresco Labs 3-Year RORE % Chart

Cresco Labs Annual Data
Trend Jan16 Jan17 Jan18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.14 9.94 -22.82 -34.92 -16.93

Cresco Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.83 -47.87 -67.97 -16.93 -11.20

FRA:6CQ vs ZTS, UTHR: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cresco Labs 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Cresco Labs's 3-Year RORE % falls into.


FRA:6CQ
42GF Score
Cresco Labs Inc FRA:6CQ
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cresco Labs 3-Year RORE % Calculation

Cresco Labs's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.326--0.435 )/( -0.973-0 )
=0.109/-0.973
=-11.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -11.20 mean?
Cresco Labs (FRA:6CQ) has a 3-Year RORE % of -11.20 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cresco Labs and its competitors. According to the industry distribution chart, Cresco Labs ranks #546 out of 937 companies in the Drug Manufacturers industry, placing it in the top 58.3%.
Is Cresco Labs' 3-Year RORE % too high?
Cresco Labs' current 3-Year RORE % is -11.20. Based on the distribution chart, Cresco Labs ranks #546 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cresco Labs has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #546 out of 937 companies for 3-Year RORE %. This places Cresco Labs in the lower half of its industry. The industry median 3-Year RORE % is 3.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.17, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current 3-Year RORE % is -11.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.78, compared to a current price of €0.60 — trading 23.5% below its estimated fair value. The current 3-Year RORE % is -11.20. Cresco Labs' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current 3-Year RORE % is -11.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cresco Labs (FRA:6CQ) Overvalued in 2026?

Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued. The current stock price of €0.60 is trading 23.5% below its estimated GF Value™ of €0.78. GuruFocus considers Cresco Labs to be Modestly Undervalued.

Key valuation signals for FRA:6CQ:

  • 3-Year RORE %: -11.20
  • GF Value™: €0.78 vs. price of €0.60 (23.5% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cresco Labs Business Description

Address 600 W. Fulton Street, Suite 800, Chicago, IL, USA, 60661
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
42GF Score

Get the complete analysis for FRA:6CQ

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€0.78
GF Value